UBS Group AG Cuts Stake in LifeStance Health Group, Inc. $LFST

UBS Group AG lowered its stake in shares of LifeStance Health Group, Inc. (NASDAQ:LFST) by 68.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 435,255 shares of the company’s stock after selling 966,193 shares during the period. UBS Group AG’s holdings in LifeStance Health Group were worth $3,064,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Bayesian Capital Management LP purchased a new stake in shares of LifeStance Health Group during the second quarter worth about $52,000. Vanguard Personalized Indexing Management LLC acquired a new position in LifeStance Health Group during the third quarter worth about $72,000. CIBC Bancorp USA Inc. acquired a new position in LifeStance Health Group during the third quarter worth about $78,000. Jump Financial LLC acquired a new position in LifeStance Health Group during the second quarter worth about $79,000. Finally, Park Edge Advisors LLC boosted its position in LifeStance Health Group by 14.4% during the fourth quarter. Park Edge Advisors LLC now owns 11,863 shares of the company’s stock worth $84,000 after acquiring an additional 1,495 shares during the last quarter. Hedge funds and other institutional investors own 85.50% of the company’s stock.

Insider Buying and Selling at LifeStance Health Group

In other LifeStance Health Group news, Director Eric Shuey sold 243,362 shares of the stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $8.02, for a total value of $1,951,763.24. Following the sale, the director directly owned 867,562 shares of the company’s stock, valued at approximately $6,957,847.24. This represents a 21.91% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Robert Bessler sold 575,034 shares of the stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $8.02, for a total transaction of $4,611,772.68. Following the completion of the sale, the director directly owned 986,931 shares in the company, valued at approximately $7,915,186.62. This represents a 36.81% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 11,182,996 shares of company stock worth $85,295,948 in the last ninety days. 3.20% of the stock is owned by insiders.

LifeStance Health Group Stock Performance

NASDAQ:LFST opened at $7.39 on Tuesday. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.48 and a quick ratio of 1.48. The firm has a market capitalization of $2.87 billion, a price-to-earnings ratio of 123.17 and a beta of 1.20. The company’s 50-day moving average is $6.98 and its two-hundred day moving average is $6.91. LifeStance Health Group, Inc. has a 1-year low of $3.74 and a 1-year high of $8.89.

LifeStance Health Group (NASDAQ:LFST) last posted its earnings results on Wednesday, May 6th. The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.03. The company had revenue of $403.48 million for the quarter, compared to analyst estimates of $387.46 million. LifeStance Health Group had a net margin of 1.55% and a return on equity of 1.56%. The firm’s revenue was up 21.2% compared to the same quarter last year. Analysts forecast that LifeStance Health Group, Inc. will post 0.12 EPS for the current year.

LifeStance Health Group announced that its Board of Directors has approved a stock buyback program on Wednesday, February 25th that authorizes the company to buyback $100.00 million in outstanding shares. This buyback authorization authorizes the company to purchase up to 3.6% of its stock through open market purchases. Stock buyback programs are often a sign that the company’s board of directors believes its shares are undervalued.

Analyst Ratings Changes

LFST has been the topic of a number of recent research reports. Barclays boosted their price target on shares of LifeStance Health Group from $8.00 to $9.00 and gave the stock an “overweight” rating in a research report on Friday, March 6th. Zacks Research upgraded shares of LifeStance Health Group from a “hold” rating to a “strong-buy” rating in a research report on Monday, April 27th. JPMorgan Chase & Co. boosted their price target on shares of LifeStance Health Group from $8.00 to $9.00 and gave the stock a “neutral” rating in a research report on Thursday, May 14th. Canaccord Genuity Group boosted their price target on shares of LifeStance Health Group from $9.00 to $10.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Finally, UBS Group boosted their price target on shares of LifeStance Health Group from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, LifeStance Health Group has a consensus rating of “Buy” and an average target price of $9.86.

LifeStance Health Group Company Profile

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.